CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy

References

• Pfirschke C , Engblom C , Rickelt S , Cortez-Retamozo V , Garris C , Pucci F , Yamazaki T , Poirier-Colame V , Newton A , Redouane Y , et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity. 2016;44:343-54. doi:10.1016/j.immuni.2015.11.024. PMID:26872698
   PubMed Web of Science ®Google Scholar
• Michaud M , Martins I , Sukkurwala AQ , Adjemian S , Ma Y , Pellegatti P , Shen S , Kepp O , Scoazec M , Mignot G , et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334:1573-7. doi:10.1126/science.1208347. PMID:22174255
   PubMed Web of Science ®Google Scholar
• Maio M , Grob JJ , Aamdal S , Bondarenko I , Robert C , Thomas L , Garbe C , Chiarion-Sileni V , Testori A , Chen TT , et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33:1191-6.doi:10.1200/JCO.2014.56.6018. PMID:25713437
   PubMed Web of Science ®Google Scholar
• Yan Y, Robert C, Larkin J, Ascierto PA, Dreno B, Maio M, Garbe C, Chapman PB, Sosman JA, Wongchenko MJ, et al. Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone. Annals of Oncology 2016; 27(Suppl_6):1111O
   Web of Science ®Google Scholar
• Eggermont AMM , Chiarion-Sileni V , Grob JJ , Dummer R , Wolchok JD , Schmidt H , Hamid O , Robert C , Ascierto PA , Richards JM , et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522-30. doi:10.1016/S1470-2045(15)70122-1. PMID:25840693
   PubMed Web of Science ®Google Scholar
• Blank CU , Haanen JB , Ribas A & Schumacher TN. CANCER IMMUNOLOGY. The ‘cancer immunogram’. Science. 2016;352:658-60. doi:10.1126/science.aaf2834. PMID:27151852
   PubMed Web of Science ®Google Scholar
• Daud AI , Wolchok JD , Robert C , Hwu WJ , Weber JS , Ribas A , Hodi FS , Joshua AM , Kefford R , Hersey P , et al. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol 2016;34:4102-4109. doi:10.1200/JCO.2016.67.2477. PMID:27863197
   PubMed Web of Science ®Google Scholar
• Herbst RS , Baas P , Kim DW , Felip E , Pérez-Gracia JL , Han JY , Molina J , Kim JH , Arvis CD , Ahn MJ , et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England). 2016;387:1540-50. doi:10.1016/S0140-6736(15)01281-7. PMID:26712084
   PubMed Web of Science ®Google Scholar
• Ferris RL, Licitra L, Fayette J, Even C, Blumenschein GR, Harrington K, Guigay J, Vokes EE, Saba NF, Haddad RI , et al. Nivolumab (Nivo) vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use. Journal of Clinical Oncology. 2017;35:15(suppl):6020.
   Google Scholar
• Armand P . Immune checkpoint blockade in hematologic malignancies. Blood. 2015;125:3393-400. doi:10.1182/blood-2015-02-567453. PMID:25833961
   PubMed Web of Science ®Google Scholar
• Snyder A , Makarov V , Merghoub T , Yuan J , Zaretsky JM , Desrichard A , Walsh LA , Postow MA , Wong P , Ho TS , et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N Engl J Med. 2014;371:2189-99. doi:10.1056/NEJMoa1406498. PMID:25409260
   PubMed Web of Science ®Google Scholar
• Rizvi NA , Hellmann MD , Snyder A , Kvistborg P , Makarov V , Havel JJ , Lee W , Yuan J , Wong P , Ho TS , et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (80-.). 2015;348:124-8. doi:10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Le DT , Uram JN , Wang H , Bartlett BR , Kemberling H , Eyring AD , Skora AD , Luber BS , Azad NS , Laheru D , et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509-20. doi:10.1056/NEJMoa1500596. PMID:26028255
   PubMed Web of Science ®Google Scholar
• Rosenberg JE , Hoffman-Censits J , Powles T , van der Heijden MS , Balar AV , Necchi A , Dawson N , O'Donnell PH , Balmanoukian A , Loriot Y , et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England). 2016;387:1909-20. doi:10.1016/S0140-6736(16)00561-4. PMID:26952546
   PubMed Web of Science ®Google Scholar
• Roh W , Chen P-L , Reuben A , Spencer CN , Prieto PA , Miller JP , Gopalakrishnan V , Wang F , Cooper ZA , Reddy SM , et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9(379):eaah3560. doi:10.1126/scitranslmed.aah3560.
   Web of Science ®Google Scholar
• Zaretsky JM , Garcia-Diaz A , Shin DS , Escuin-Ordinas H , Hugo W , Hu-Lieskovan S , Torrejon DY , Abril-Rodriguez G , Sandoval S , Barthly L , et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375:819-29. doi:10.1056/NEJMoa1604958. PMID:27433843
   PubMed Web of Science ®Google Scholar
• Larkin J , Chiarion-Sileni V , Gonzalez R , Grob JJ , Cowey CL , Lao CD , Schadendorf D , Dummer R , Smylie M , Rutkowski P , et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373:23-34. doi:10.1056/NEJMoa1504030. PMID:26027431
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE, Gerber DE, Juergens R, Shepherd F, et al. ORAL01.03: CheckMate 012: Safety and efficacy of first-line nivolumab and ipilimumab in advanced NSCLC. Journal of Thoracic Oncology. 2016; 11(11):S250–S251. doi:10.1016/j.jtho.2016.09.008
   Google Scholar
• Zakharia Y , et al. Interim Analysis of the Phase 2 Clinical Trial of the IDO Pathway Inhibitor Indoximod in Combination With Pembrolizumab for Patients With Advanced Melanoma. AACR Conf. 2017.
   Google Scholar
• Brahmer J , Reckamp KL , Baas P , Crinò L , Eberhardt WE , Poddubskaya E , Antonia S , Pluzanski A , Vokes EE , Holgado E , et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-35. doi:10.1056/NEJMoa1504627. PMID:26028407
   PubMed Web of Science ®Google Scholar
• Schreibelt G , Bol KF , Westdorp H , Wimmers F , Aarntzen EH , Duiveman-de Boer T , van de Rakt MW , Scharenborg NM , de Boer AJ , Pots JM , et al. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clin Cancer Res. 2016;22:2155-66. doi:10.1158/1078-0432.CCR-15-2205. PMID:26712687
   PubMed Web of Science ®Google Scholar
• Hammink R , Mandal S , Eggermont LJ , Nooteboom M , Willems PH , Tel J , Rowan AE , Figdor CG , Blank KG . Controlling T-Cell Activation with Synthetic Dendritic Cells Using the Multivalency Effect. ACS omega 2, 937-945 (2017) .doi:10.1021/acsomega.6b00436. PMID:28393131
   PubMed Web of Science ®Google Scholar
• Mandal S , Hammink R , Tel J , Eksteen-Akeroyd ZH , Rowan AE , Blank K , Figdor CG . Polymer-based synthetic dendritic cells for tailoring robust and multifunctional T cell responses. ACS Chem Biol. 2015;10:485-92. doi:10.1021/cb500455g. PMID:25372624
   PubMed Web of Science ®Google Scholar
• Castle JC , Kreiter S , Diekmann J , Löwer M , van de Roemer N , de Graaf J , Selmi A , Diken M , Boegel S , Paret C , et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72:1081-91. doi:10.1158/0008-5472.CAN-11-3722. PMID:22237626
   PubMed Web of Science ®Google Scholar
• Kreiter S , Vormehr M , van de Roemer N , Diken M , Löwer M , Diekmann J , Boegel S , Schrörs B , Vascotto F , Castle JC , et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520:692-696. doi:10.1038/nature14426. PMID:25901682
   PubMed Web of Science ®Google Scholar
• Kranz LM , Diken M , Haas H , Kreiter S , Loquai C , Reuter KC , Meng M , Fritz D , Vascotto F , Hefesha H , et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396-401. doi:10.1038/nature18300. PMID:27281205
   PubMed Web of Science ®Google Scholar
• Geukes Foppen MH , Donia M , Svane IM , Haanen JBAG . Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Mol Oncol. 2015;9:1918-35. doi:10.1016/j.molonc.2015.10.018. PMID:26578452
   PubMed Web of Science ®Google Scholar
• Maude SL , Frey N , Shaw PA , Aplenc R , Barrett DM , Bunin NJ , Chew A , Gonzalez VE , Zheng Z , Lacey SF , et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507-17. doi:10.1056/NEJMoa1407222. PMID:25317870
   PubMed Web of Science ®Google Scholar
• Lee DW , Kochenderfer JN , Stetler-Stevenson M , Cui YK , Delbrook C , Feldman SA , Fry TJ , Orentas R , Sabatino M , Shah NN , et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (London, England). 2015;385:517-28. doi:10.1016/S0140-6736(14)61403-3. PMID:25319501
   PubMed Web of Science ®Google Scholar
• Davila ML , Riviere I , Wang X , Bartido S , Park J , Curran K , Chung SS , Stefanski J , Borquez-Ojeda O , Olszewska M , et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25. doi:10.1126/scitranslmed.3008226. PMID:24553386
   PubMed Web of Science ®Google Scholar
• Cohen CJ , Gartner JJ , Horovitz-Fried M , Shamalov K , Trebska-McGowan K , Bliskovsky VV , Parkhurst MR , Ankri C , Prickett TD , Crystal JS , et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 2015;125:3981-91. doi:10.1172/JCI82416. PMID:26389673
   PubMed Web of Science ®Google Scholar
• Robbins PF , Lu YC , El-Gamil M , Li YF , Gross C , Gartner J , Lin JC , Teer JK , Cliften P , Tycksen E , et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19:747-52. doi:10.1038/nm.3161. PMID:23644516
   PubMed Web of Science ®Google Scholar
• Linnemann C , van Buuren MM , Bies L , Verdegaal EM , Schotte R , Calis JJ , Behjati S , Velds A , Hilkmann H , Atmioui DE , et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4 + T cells in human melanoma. Nat Med. 2015;21:81-5. doi:10.1038/nm.3773. PMID:25531942
   PubMed Web of Science ®Google Scholar
• Strønen E , Toebes M , Kelderman S , van Buuren MM , Yang W , van Rooij N , Donia M , Böschen ML , Lund-Johansen F , Olweus J , et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science. 2016;352:1337-41. .doi:10.1126/science.aaf2288. PMID:27198675
   PubMed Web of Science ®Google Scholar
• Eberl G , Di Santo JP , Vivier E . The brave new world of innate lymphoid cells. Nat Immunol. 2015;16:1-5. doi:10.1038/ni.3059. PMID:25521670
   PubMed Web of Science ®Google Scholar
• Kiessling R , Klein E , Wigzell H . ‘Natural’ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5:112-7. doi:10.1002/eji.1830050208. PMID:1234049
   PubMed Web of Science ®Google Scholar
• Kiessling R , Klein E , Pross H , Wigzell H . ‘Natural’ killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol. 1975;5:117-21. doi:10.1002/eji.1830050209. PMID:1086218
   PubMed Web of Science ®Google Scholar
• Romagné F , André P , Spee P , Zahn S , Anfossi N , Gauthier L , Capanni M , Ruggeri L , Benson DM Jr , Blaser BW , et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114:2667-77. doi:10.1182/blood-2009-02-206532. PMID:19553639
   PubMed Web of Science ®Google Scholar
• Sola C , André P , Lemmers C , Fuseri N , Bonnafous C , Bléry M , Wagtmann NR , Romagné F , Vivier E , Ugolini S . Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009;106:12879-84. doi:10.1073/pnas.0901653106. PMID:19561305
   PubMed Web of Science ®Google Scholar
• Kohrt HE , Thielens A , Marabelle A , Sagiv-Barfi I , Sola C , Chanuc F , Fuseri N , Bonnafous C , Czerwinski D , Rajapaksa A , et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014;123:678-86. doi:10.1182/blood-2013-08-519199. PMID:24326534
   PubMed Web of Science ®Google Scholar
• Ferris RL , Blumenschein G Jr , Fayette J , Guigay J , Colevas AD , Licitra L , Harrington K , Kasper S , Vokes EE , Even C , et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856-1867; .doi:10.1056/NEJMoa1602252. PMID:27718784
   PubMed Web of Science ®Google Scholar
• Chiossone L & Vivier E . Immune checkpoints on innate lymphoid cells. J Exp Med. 2017;214:1561-1563. doi:10.1084/jem.20170763. PMID:28515074
   PubMed Web of Science ®Google Scholar
• Rodríguez-Paredes M & Esteller M . Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330-9. doi:10.1038/nm.2305. PMID:21386836
   PubMed Web of Science ®Google Scholar
• Esteller M . Epigenetics in cancer. N Engl J Med. 2008;358:1148-59. .doi:10.1056/NEJMra072067. PMID:18337604
   PubMed Web of Science ®Google Scholar
• Martínez-Cardús A , Moran S , Musulen E , Moutinho C , Manzano JL , Martinez-Balibrea E , Tierno M , Élez E , Landolfi S , Lorden P , et al. Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. Gastroenterology. 2016;151:961-972. .doi:10.1053/j.gastro.2016.08.001. PMID:27521480
   PubMed Web of Science ®Google Scholar
• Moran S , Martínez-Cardús A , Sayols S , Musulén E , Balañá C , Estival-Gonzalez A , Moutinho C , Heyn H , Diaz-Lagares A , de Moura MC , et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol 2016;17:1386-1395. doi:10.1016/S1470-2045(16)30297-2. PMID:27575023
   PubMed Web of Science ®Google Scholar
• Sahin U , Koslowski M , Dhaene K , Usener D , Brandenburg G , Seitz G , Huber C , Türeci O . Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 2008;14:7624-34. doi:10.1158/1078-0432.CCR-08-1547. PMID:19047087
   PubMed Web of Science ®Google Scholar
• Wöll S , Schlitter AM , Dhaene K , Roller M , Esposito I , Sahin U , Türeci Ö . Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2013;134:731-9. doi:10.1002/ijc.28400. PMID:23900716
   PubMed Web of Science ®Google Scholar
• Schuler M , et al. Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gast. Ann Oncol. 2016;27(6):207-242. doi:10.1093/annonc/mdw371
   Web of Science ®Google Scholar
• Al-Batran S-E, Schuler MH, Zvirbule Z, Manikhas G, Lordick F, Rusyn A, Vynnyk Y, Vynnychenko T, Fadeeva N, Nechaeva M, et al. FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology. 2016;34(18_suppl):LBA4001-LBA4001.
   Google Scholar
• Lordick F, Schuler M, Al-Batran S-E, Zvirbule Z, Manikhas G, Rusyn A, Vinnyk Y, Vynnychenko I, Fadeeva N, Nechaeva M, et al. 220O Claudin 18.2 – a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. Annals of Oncology 2016;27(suppl_9):mdw582.001. doi:10.1093/annonc/mdw582.001
   Web of Science ®Google Scholar
• Mussai F , De Santo C , Abu-Dayyeh I , Booth S , Quek L , McEwen-Smith RM , Qureshi A , Dazzi F , Vyas P , Cerundolo V . Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 2013;122:749-758. doi:10.1182/blood-2013-01-480129. PMID:23733335
   PubMed Web of Science ®Google Scholar
• Hunder NN , Wallen H , Cao J , Hendricks DW , Reilly JZ , Rodmyre R , Jungbluth A , Gnjatic S , Thompson JA , Yee C . Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358:2698-703. doi:10.1056/NEJMoa0800251. PMID:18565862
   PubMed Web of Science ®Google Scholar
• Kenter GG , Welters MJ , Valentijn AR , Lowik MJ , Berends-van der Meer DM , Vloon AP , Essahsah F , Fathers LM , Offringa R , Drijfhout JW , et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361:1838-47. doi:10.1056/NEJMoa0810097. PMID:19890126
   PubMed Web of Science ®Google Scholar
• Quezada Sa , Simpson TR , Peggs KS , Merghoub T , Vider J , Fan X , Blasberg R , Yagita H , Muranski P , Antony PA , et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207:637-50. doi:10.1084/jem.20091918. PMID:20156971
   PubMed Web of Science ®Google Scholar
• Corthay A , Skovseth DK , Lundin KU , Røsjø E , Omholt H , Hofgaard PO , Haraldsen G , Bogen B . Primary antitumor immune response mediated by CD4+ T cells. Immunity. 2005;22:371-383. doi:10.1016/j.immuni.2005.02.003. PMID:15780993
   PubMed Web of Science ®Google Scholar
• Péguillet I , Milder M , Louis D , Vincent-Salomon A , Dorval T , Piperno-Neumann S , Scholl SM , Lantz O . High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res. 2014;74:2204-2216. doi:10.1158/0008-5472.CAN-13-2269. PMID:24535711
   PubMed Web of Science ®Google Scholar
• Flament H , Alonso Ramirez R , Prémel V , Joncker NT , Jacquet A , Scholl S , Lantz O . Modeling the Specific CD4+ T Cell Response against a Tumor Neoantigen. J Immunol. 2015;194:3501-3512. doi:10.4049/jimmunol.1402405. PMID:25732731
   PubMed Web of Science ®Google Scholar
• Kowalewski DJ , Schuster H , Backert L , Berlin C , Kahn S , Kanz L , Salih HR , Rammensee HG , Stevanovic S , Stickel JS . HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2015;112:E166−75. doi:10.1073/pnas.1416389112. PMID:25548167
   PubMed Web of Science ®Google Scholar
• Yadav M , Jhunjhunwala S , Phung QT , Lupardus P , Tanguay J , Bumbaca S , Franci C , Cheung TK , Fritsche J , Weinschenk T , et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515:572-6. doi:10.1038/nature14001. PMID:25428506
   PubMed Web of Science ®Google Scholar
• Stickel JS , Weinzierl AO , Hillen N , Drews O , Schuler MM , Hennenlotter J , Wernet D , Müller CA , Stenzl A , Rammensee HG , et al. HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol. Immunother. 2009;58:1407-17. doi:10.1007/s00262-008-0655-6. PMID:19184600
   PubMed Web of Science ®Google Scholar
• Stickel JS , Stickel N , Hennenlotter J , Klingel K , Stenzl A , Rammensee HG , Stevanović S . Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation. BMC Urol. 2011;11:1. doi:10.1186/1471-2490-11-1. PMID:21251276
   PubMed Web of Science ®Google Scholar
• Weinschenk T , Gouttefangeas C , Schirle M , Obermayr F , Walter S , Schoor O , Kurek R , Loeser W , Bichler KH , Wernet D , et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 2002;62:5818-27. doi:10.1038/nm.2883. PMID:12384544
   PubMed Web of Science ®Google Scholar
• Walter S , Weinschenk T , Stenzl A , Zdrojowy R , Pluzanska A , Szczylik C , Staehler M , Brugger W , Dietrich PY , Mendrzyk R , et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18:1254-61. PMID:22842478
   PubMed Web of Science ®Google Scholar
• Spranger S , Bao R & Gajewski TF . Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231-5. doi:10.1038/nature14404. PMID:25970248
   PubMed Web of Science ®Google Scholar
• Liu C , Peng W , Xu C , Lou Y , Zhang M , Wargo JA , Chen JQ , Li HS , Watowich SS , Yang Y , et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res. 2013;19:393-403. doi:10.1158/1078-0432.CCR-12-1626. PMID:23204132
   PubMed Web of Science ®Google Scholar
• Frederick DT , Piris A , Cogdill AP , Cooper ZA , Lezcano C , Ferrone CR , Mitra D , Boni A , Newton LP , Liu C , et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19:1225-31. doi:10.1158/1078-0432.CCR-12-1630. PMID:23307859
   PubMed Web of Science ®Google Scholar
• Peng W , Chen JQ , Liu C , Malu S , Creasy C , Tetzlaff MT , Xu C , McKenzie JA , Zhang C , Liang X , et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6:202-16. doi:10.1158/2159-8290.CD-15-0283. PMID:26645196
   PubMed Web of Science ®Google Scholar
• Britten CM , Gouttefangeas C , Welters MJ , Pawelec G , Koch S , Ottensmeier C , Mander A , Walter S , Paschen A , Müller-Berghaus J , et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother. 2008;57:289-302. doi:10.1007/s00262-007-0378-0. PMID:17721783
   PubMed Web of Science ®Google Scholar
• Moodie Z , Price L , Gouttefangeas C , Mander A , Janetzki S , Löwer M , Welters MJ , Ottensmeier C , van der Burg SH , Britten CM . Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother. 2010;59:1489-501. doi:10.1007/s00262-010-0875-4. PMID:20549207
   PubMed Web of Science ®Google Scholar
• Welters MJP , Gouttefangeas C , Ramwadhdoebe TH , Letsch A , Ottensmeier CH , Britten CM , van der Burg SH . Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother. 2012;61:967-78. doi:10.1007/s00262-012-1282-9. PMID:22714399
   PubMed Web of Science ®Google Scholar
• Santegoets SJ , Dijkgraaf EM , Battaglia A , Beckhove P , Britten CM , Gallimore A , Godkin A , Gouttefangeas C , de Gruijl TD , Koenen HJ , et al. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother. 2015;64:1271-86. doi:10.1007/s00262-015-1729-x. PMID:26122357
   PubMed Web of Science ®Google Scholar
• Mandruzzato S , Brandau S , Britten CM , Bronte V , Damuzzo V , Gouttefangeas C , Maurer D , Ottensmeier C , van der Burg SH , Welters MJ , et al. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol Immunother. 2016;65:161-9. doi:10.1007/s00262-015-1782-5. PMID:26728481
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM , Santegoets SJ , Reyners AK , Goedemans R , Nijman HW , van Poelgeest MI , van Erkel AR , Smit VT , Daemen TA , van der Hoeven JJ , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget. 2015;6:32228-43. doi:10.18632/oncotarget.4772. PMID:26334096
   PubMed Web of Science ®Google Scholar